AI Summary
This study indicates that the presence of ctDNA in blood samples can serve as a predictive marker for determining which colorectal cancer patients should receive chemotherapy after tumor removal surgery. This finding has the potential to personalize treatment decisions and improve outcomes for patients.
Results from a new study suggest that the presence of circulating tumor DNA (ctDNA) in blood samples can predict which patients with colorectal cancer should and shouldn’t get chemotherapy after surgery to remove their tumors.